Chengdu Olymvax Biopharmaceuticals Inc.

SHSE:688319 Stock Report

Market Cap: CN¥5.1b

Chengdu Olymvax Biopharmaceuticals Past Earnings Performance

Past criteria checks 0/6

Chengdu Olymvax Biopharmaceuticals's earnings have been declining at an average annual rate of -25.9%, while the Biotechs industry saw earnings growing at 7.6% annually. Revenues have been growing at an average rate of 13.6% per year.

Key information

-25.9%

Earnings growth rate

-26.5%

EPS growth rate

Biotechs Industry Growth11.3%
Revenue growth rate13.6%
Return on equity-1.6%
Net Margin-1.6%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Chengdu Olymvax Biopharmaceuticals Inc. (SHSE:688319) Stock Rockets 40% As Investors Are Less Pessimistic Than Expected

Oct 09
Chengdu Olymvax Biopharmaceuticals Inc. (SHSE:688319) Stock Rockets 40% As Investors Are Less Pessimistic Than Expected

We Think Chengdu Olymvax Biopharmaceuticals (SHSE:688319) Has A Fair Chunk Of Debt

Sep 30
We Think Chengdu Olymvax Biopharmaceuticals (SHSE:688319) Has A Fair Chunk Of Debt

What Chengdu Olymvax Biopharmaceuticals Inc.'s (SHSE:688319) 26% Share Price Gain Is Not Telling You

Jun 24
What Chengdu Olymvax Biopharmaceuticals Inc.'s (SHSE:688319) 26% Share Price Gain Is Not Telling You

Is There An Opportunity With Chengdu Olymvax Biopharmaceuticals Inc.'s (SHSE:688319) 27% Undervaluation?

May 28
Is There An Opportunity With Chengdu Olymvax Biopharmaceuticals Inc.'s (SHSE:688319) 27% Undervaluation?

Chengdu Olymvax Biopharmaceuticals Inc. (SHSE:688319) Shares May Have Slumped 25% But Getting In Cheap Is Still Unlikely

Apr 18
Chengdu Olymvax Biopharmaceuticals Inc. (SHSE:688319) Shares May Have Slumped 25% But Getting In Cheap Is Still Unlikely

These 4 Measures Indicate That Chengdu Olymvax Biopharmaceuticals (SHSE:688319) Is Using Debt Extensively

Mar 26
These 4 Measures Indicate That Chengdu Olymvax Biopharmaceuticals (SHSE:688319) Is Using Debt Extensively

Revenue & Expenses Breakdown

How Chengdu Olymvax Biopharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SHSE:688319 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24530-9374134
30 Jun 24489-39357148
31 Mar 24500-12356144
31 Dec 2349618338115
30 Sep 2352917365132
30 Jun 2354824367132
31 Mar 2356137357124
31 Dec 2254727364122
30 Sep 225737036893
30 Jun 225519735865
31 Mar 224778131562
31 Dec 2148710830556
30 Sep 214057826846
30 Jun 213786525649
31 Mar 213285022545
31 Dec 203203622943
31 Dec 19179-3115344
31 Dec 1876-195531
30 Jun 186314470
31 Mar 18547460
31 Dec 17451450
30 Sep 1726-23500
30 Jun 177-48540
31 Mar 174-52550
31 Dec 160-56550
30 Sep 160-51520
30 Jun 160-47490
31 Mar 160-50510
31 Dec 150-52520
31 Dec 140-30260

Quality Earnings: 688319 is currently unprofitable.

Growing Profit Margin: 688319 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 688319 is unprofitable, and losses have increased over the past 5 years at a rate of 25.9% per year.

Accelerating Growth: Unable to compare 688319's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 688319 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (1.3%).


Return on Equity

High ROE: 688319 has a negative Return on Equity (-1.6%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies